S
Sona Narula
Researcher at Children's Hospital of Philadelphia
Publications - 23
Citations - 566
Sona Narula is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Multiple sclerosis & Medicine. The author has an hindex of 9, co-authored 18 publications receiving 459 citations. Previous affiliations of Sona Narula include University of Paris-Sud & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease
Russell C. Dale,Fabienne Brilot,Lisa V. Duffy,Marinka Twilt,Amy Waldman,Sona Narula,Eyal Muscal,Kumaran Deiva,Erik Andersen,Michael Eyre,Despina Eleftheriou,Paul A. Brogan,Rachel Kneen,Gulay Alper,Banu Anlar,Evangeline Wassmer,Kirsten Heineman,Cheryl Hemingway,Catherine J. Riney,Andrew J. Kornberg,Marc Tardieu,Amber Stocco,Brenda Banwell,Mark P. Gorman,Susanne M. Benseler,Ming K. Lim +25 more
TL;DR: The data support an off-label use of rituximab in pediatric autoimmune and inflammatory CNS disorders, although the significant risk of infectious complications suggests ritUXimab should be restricted to disorders with significant morbidity and mortality.
Journal ArticleDOI
Pediatric multiple sclerosis
TL;DR: Ongoing research in the field of pediatric MS aims to better understand the epidemiologic factors involved in the pathobiology, safety and efficacy of disease-modifying treatments, and long-term prognosis, particularly of cognitive development and academic potential.
Journal ArticleDOI
Status Epilepticus and Refractory Status Epilepticus Management
Nicholas S. Abend,David Bearden,Ingo Helbig,Jennifer L. McGuire,Sona Narula,Jessica A. Panzer,Alexis A. Topjian,Dennis J. Dlugos +7 more
TL;DR: The management of pediatric SE and refractory SE is reviewed, which involves "emergent" treatment with benzodiazepines followed by "urgent" therapy with other antiseizure medications.
Journal ArticleDOI
Radiologically isolated syndrome in children: Clinical and radiologic outcomes.
Naila Makhani,Christine Lebrun,Aksel Siva,David Brassat,Clarisse Carra Dallière,Jérôme De Seze,Wei Du,Francoise Durand Dubief,Orhun H. Kantarci,Megan Langille,Sona Narula,Jean Pelletier,Juan Ignacio Rojas,Eugene D. Shapiro,Robert Thompson Stone,Mar Tintoré,Ugur Uygunoglu,Patrick Vermersch,Evangeline Wassmer,Darin T. Okuda,Daniel Pelletier +20 more
TL;DR: Children with RIS had a substantial risk of subsequent clinical symptoms and/or radiologic evolution and the presence of oligoclonal bands in CSF and spinal cord lesions on MRI were associated with an increased risk of a first clinical event.
Journal ArticleDOI
Treatment of Pediatric Multiple Sclerosis
TL;DR: In this article, a number of injectable, oral, and intravenous treatments for pediatric multiple sclerosis (MS) have been evaluated in clinical trials, including intravenous methylprednisolone, interferon beta, and natalizumab.